These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
415 related articles for article (PubMed ID: 37326115)
1. Prevention of Parkinson's Disease: From Risk Factors to Early Interventions. Ng MG; Chan BJL; Koh RY; Ng KY; Chye SM CNS Neurol Disord Drug Targets; 2024; 23(6):746-760. PubMed ID: 37326115 [TBL] [Abstract][Full Text] [Related]
2. Modifiable risk and protective factors in disease development, progression and clinical subtypes of Parkinson's disease: What do prospective studies suggest? Belvisi D; Pellicciari R; Fabbrini G; Tinazzi M; Berardelli A; Defazio G Neurobiol Dis; 2020 Feb; 134():104671. PubMed ID: 31706021 [TBL] [Abstract][Full Text] [Related]
3. Preventing Parkinson's Disease: An Environmental Agenda. De Miranda BR; Goldman SM; Miller GW; Greenamyre JT; Dorsey ER J Parkinsons Dis; 2022; 12(1):45-68. PubMed ID: 34719434 [TBL] [Abstract][Full Text] [Related]
4. Biomarkers of Parkinson's disease: present and future. Miller DB; O'Callaghan JP Metabolism; 2015 Mar; 64(3 Suppl 1):S40-6. PubMed ID: 25510818 [TBL] [Abstract][Full Text] [Related]
5. Artificial intelligence in Parkinson's disease: Early detection and diagnostic advancements. Reddy A; Reddy RP; Roghani AK; Garcia RI; Khemka S; Pattoor V; Jacob M; Reddy PH; Sehar U Ageing Res Rev; 2024 Aug; 99():102410. PubMed ID: 38972602 [TBL] [Abstract][Full Text] [Related]
6. Can Biomarkers Help the Early Diagnosis of Parkinson's Disease? Le W; Dong J; Li S; Korczyn AD Neurosci Bull; 2017 Oct; 33(5):535-542. PubMed ID: 28866850 [TBL] [Abstract][Full Text] [Related]
7. Identifying comorbidities and lifestyle factors contributing to the cognitive profile of early Parkinson's disease. Martínez-Horta S; Bejr-Kasem H; Horta-Barba A; Pascual-Sedano B; Santos-García D; de Deus-Fonticoba T; Jesús S; Aguilar M; Planellas L; García-Caldentey J; Caballol N; Vives-Pastor B; Hernández-Vara J; Cabo-Lopez I; López-Manzanares L; González-Aramburu I; Ávila-Rivera MA; Catalán MJ; López-Díaz LM; Puente V; García-Moreno JM; Borrué C; Solano-Vila B; Álvarez-Sauco M; Vela L; Escalante S; Cubo E; Carrillo-Padilla F; Martínez-Castrillo JC; Sánchez-Alonso P; Alonso-Losada MG; López-Ariztegui N; Gastón I; Blázquez-Estrada M; Seijo-Martínez M; Rúiz-Martínez J; Valero-Merino C; Kurtis M; de Fábregues-Boixar O; González-Ardura J; Prieto-Jurczynska C; Martinez-Martin P; Mir P; Kulisevsky J; BMC Neurol; 2021 Dec; 21(1):477. PubMed ID: 34879838 [TBL] [Abstract][Full Text] [Related]
8. Neuroinflammation as a Common Mechanism Associated with the Modifiable Risk Factors for Alzheimer's and Parkinson's Diseases. McKenzie JA; Spielman LJ; Pointer CB; Lowry JR; Bajwa E; Lee CW; Klegeris A Curr Aging Sci; 2017; 10(3):158-176. PubMed ID: 28302047 [TBL] [Abstract][Full Text] [Related]
15. The epidemiology of Parkinson's disease: risk factors and prevention. Ascherio A; Schwarzschild MA Lancet Neurol; 2016 Nov; 15(12):1257-1272. PubMed ID: 27751556 [TBL] [Abstract][Full Text] [Related]
16. Cerebrospinal Fluid Biomarkers for Target Engagement and Efficacy in Clinical Trials for Alzheimer's and Parkinson's Diseases. Parnetti L; Eusebi P; Lleó A Front Neurol Neurosci; 2016; 39():117-23. PubMed ID: 27463974 [TBL] [Abstract][Full Text] [Related]
17. Reducing neuroinflammation via therapeutic compounds and lifestyle to prevent or delay progression of Parkinson's disease. Kip E; Parr-Brownlie LC Ageing Res Rev; 2022 Jun; 78():101618. PubMed ID: 35395416 [TBL] [Abstract][Full Text] [Related]
18. New markers in Parkinson's disease. Bougea A Adv Clin Chem; 2020; 96():137-178. PubMed ID: 32362317 [TBL] [Abstract][Full Text] [Related]
19. Lifestyle Modulators of Neuroplasticity in Parkinson's Disease: Evidence in Human Neuroimaging Studies. Paola Caminiti S; Gallo S; Menegon F; Naldi A; Comi C; Tondo G CNS Neurol Disord Drug Targets; 2024; 23(5):602-613. PubMed ID: 37326116 [TBL] [Abstract][Full Text] [Related]